Mineralys Seeks First-To-Market Edge In Uncontrolled Hypertension

 
• By Joseph Haas

Battling AstraZeneca in the aldosterone inhibitor space, Mineralys reports Phase III data showing lorundrostat can significantly decrease uncontrolled/resistant blood pressure at six weeks.

Gloved hand holding a blood pressure meter, indicating high blood pressure
Mineralys shows its aldosterone inhibitor can benefit patients with uncontrolled hypertension • Source: Alamy

More from Strategy

More from Therapy Areas